All In Biotech

Free tool

FAERS Monitor: Advil Allergy Sinus

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021441 or its brand name (Advil Allergy Sinus, Chlorpheniramine Maleate, Ibuprofen, Pseudoephedrine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

237

Serious

31

13% of reports

Hospitalization

3

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective79
  • product use in unapproved indication30
  • drug effective for unapproved indication23
  • drug effect incomplete13
  • dizziness10
  • somnolence9
  • headache8
  • insomnia8
  • therapeutic response unexpected8
  • nausea7
  • feeling abnormal6
  • drug ineffective for unapproved indication5
  • therapeutic product effect incomplete5
  • urticaria5
  • condition aggravated4

Reports by year received

View as table
YearReports
20062
20073
20084
20092
20104
201123
20129
201313
201416
201528
201616
20176
201814
20197
20207
202133
20228
202310
202411
202513
20268

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,922 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug effective for unapproved indicationSignal2369.747.31,491
drug effect incompleteSignal1331.818.7358
therapeutic response unexpectedSignal815.88.097
product use in unapproved indicationSignal3010.77.7258
drug ineffective for unapproved indicationSignal58.13.424
therapeutic product effect incompleteSignal56.22.617
drug ineffectiveSignal795.34.4291
somnolenceSignal94.02.117
insomniaSignal82.71.37
urticaria52.61.14
feeling abnormal62.21.03
dizziness101.81.03
condition aggravated41.20.40
headache81.10.60
nausea70.80.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.